4819 Emperor Blvd, Suite 400
About Kriya Therapeutics
Kriya is a next generation gene therapy company focused on expanding the field to new frontiers. It has built a fully-integrated technology enabled platform for rational vector design, analytical testing, and scalable manufacturing to design and develop gene therapies for diseases with well-understood underlying biology. The company’s proprietary computational platform, SIRVETM, supports its approach to de novo vector design, targeted sequence modification, and data analysis. Kriya believes that rationally engineered gene therapies can address a broad universe of diseases – and it is prepared and equipped to lead this new revolution in medicine.
15 articles with Kriya Therapeutics
Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
Twist Bioscience Corporation and Kriya Therapeutics, Inc. today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications.
Kriya forged an antibody discovery agreement with Twist to support the delivery of antibodies with AAV gene therapy in therapeutic oncology applications.
2/11/2022Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Kriya Announces the Appointment of Ma’an Muhsin, M.D., as President and Chief Medical Officer of Its Oncology Therapeutic Area Division
Kriya Therapeutics, Inc. announced today that it has appointed Ma’an Muhsin, M.D., as President and Chief Medical Officer of Kriya Oncology.
Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
Kriya Therapeutics, Inc. today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio
Kriya Therapeutics, Inc. announced today that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs).
Kriya Therapeutics Expands Leadership Team with the Appointment of Neera Ravindran, M.D., M.B.A. as Chief Financial Officer
Kriya Therapeutics, Inc. today announced the appointment of Neera Ravindran, M.D., M.B.A., as Chief Financial Officer.
Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics
Kriya Therapeutics, Inc. , a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced the appointment of Theresa Heah, M.D., MBA as Chief Medical Officer.
Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the completion of the renovation of its 51,000 square foot facility located in Research Triangle Park, North Carolina to support cGMP production of its expanding pipeline of gene therapies.
7/21/2021More money means more progress for potentially life-saving therapies. Here's a peek at some biopharma companies adding to their books this week.
Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies
Kriya Therapeutics, Inc. today announced the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
Kriya Therapeutics, based in Redwood City, Calif. and Research Triangle Park, NC, closed on a Series B financing worth $100 million.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
Kriya Therapeutics , a next generation gene therapy company focused on developing transformative treatments for highly prevalent diseases, announced today that its CEO, Shankar Ramaswamy, M.D., will present at multiple upcoming healthcare conferences in September and October. These includ
Kriya Therapeutics announces the establishment of its internal manufacturing facility for process development and scalable cGMP production of gene therapies for prevalent serious diseases
51,350 square foot operational manufacturing facility based in Research Triangle Park, North Carolina is designed to have its own fully integrated process development lab, pilot production suite, and current good manufacturing practice (cGMP) production capability